Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?
Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.
Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?
Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.
Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.